Lotte Biologics Collaborates with Merck on Syracuse Plant Expansion

CEO Lee Wonjik Strives to Raise Awareness at Sweden International Conference

Lee Won-jik, CEO of Lotte Biologics, and Andrew Bullfin, Global Head of Process Solutions at Merck Life Science Division (from left in the photo), are posing for a commemorative photo at the business agreement ceremony.

[Asia Economy Reporter Chunhee Lee] Lotte Biologics is partnering with global big pharma Merck to expand its factory in Syracuse, USA.

On the 1st, Lotte Biologics announced that it signed a business agreement with Millipore Sigma to strengthen its bio business capabilities. Through this agreement, the two companies will cooperate on the expansion of the Syracuse factory recently acquired by Lotte Biologics and jointly promote new bio-pharmaceutical businesses such as next-generation therapeutics.

Millipore Sigma is the North American life sciences division of Merck, a Germany-based big pharma. Lotte Biologics is expected to receive comprehensive technical support related to the bio business, including manufacturing solutions and personnel training, from Millipore Sigma.

The company expects that exchanges regarding bio-pharmaceutical process development and GMP (Good Manufacturing Practice) manufacturing experience possessed by Merck’s life sciences division will accelerate the promotion of the bio business. Merck’s life sciences division has supported market entry for more than 280 bio-pharmaceutical operators and has experience launching over 100 GMP pharmaceuticals in the past 10 years.

Exterior view of Lotte Biologics' Syracuse factory in the United States

Meanwhile, Lotte Biologics is also striving to enhance its global recognition by attending events hosted by foreign government agencies.

Wonjik Lee, CEO of Lotte Biologics, attended the ‘Join Sweden Summit 2022’ held in Stockholm, Sweden, on the 20th and 21st of last month, promoting Lotte Biologics’ business and engaging in global exchange opportunities. The Join Sweden Summit 2022 is an international political and economic conference where global business leaders from major trading countries including Korea, along with representatives from the Swedish government and companies totaling over 100 people, gather to explore new collaboration and investment possibilities.

In addition to Lotte Biologics, global big pharma and promising bio ventures such as Gilead, Roche, Biogen, Johnson & Johnson (J&J), Sanofi, AstraZeneca, Pfizer, and BioArctic participated. Lotte Biologics sought mutual cooperation plans with these companies and engaged in exchanges to build a potential client network.

The CEO stated, “We plan to strengthen collaboration with global bio companies to improve the quality reliability of the production volume after completing the acquisition of the Syracuse factory,” adding, “We will raise global awareness by attending major bio-pharmaceutical events and focus on securing production volume orders.”

This content was produced with the assistance of AI translation services.